MarketPulse

Phase 2 data

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial
The Motley FoolThe Motley Fool··Jonathan Ponciano

Apogee CEO Sells $1.5M in Stock Despite 100% Surge; Clinical Data Tells Real Story

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Celldex

Celldex's Barzolvolimab Shows Durable Efficacy in Retreatment Trial

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.
CLDXbarzolvolimabcold urticaria